Health leaders from 11 countries across the Pacific Islands and Somalia gathered in Manila from for a regional training led by PeerLINC. The week-long program enhanced the capacity of National Tuberculosis Program (NTP) teams to implement shorter, all-oral treatment regimens for drug-resistant tuberculosis (DR-TB) in line with the World Health Organization (WHO) recommendations.

A programmatic review of more than 200 people in Nigeria treated with BPaL/M, found 89% treatment success rates among with MDR/RR-TB and 100% for the smaller pre-XDR cohort. PeerLINC has helped to close critical training gaps in the country, which help to support effective and widespread scale-up of the regimens.

PeerLINC has expanded its training portfolio, adding four new modules, which countries participating in training programs can request. Topics of these new modules include appropriate use of alternate six- and nine-month regimens, co-management of TB and diabetes, and best practices in TB preventative therapy.

A new study confirms that six-month BPaL/M regimens for drug-resistant TB save lives and money. Compared to longer treatments, they cut costs per cure, boost completion rates, and are projected to deliver nearly US$1 billion in economic benefits in South Africa and US$800 million in the Philippines within five years.

Lupin Limited, a leading pharmaceutical company based in India, received World Health Organization (WHO) prequalification for its 200mg pretomanid tablet. This achievement adds another manufacturer to the market for a critical component of WHO-endorsed six-month drug-resistant TB treatments. Having multiple producers strengthens the global supply of pretomanid, ensures consistent quality, and drives competition that helps further lower costs.

PeerLINC’s G-TEC brought together experts from 18 countries to review complex DR-TB cases from the Philippines and India, demonstrating how collective expertise can guide safer and more effective treatment decisions.

PeerLINC Knowledge Hub joined global and national TB leaders at the 31st Philippine Coalition Against Tuberculosis (PhilCAT) Annual Convention, held August 14 to 15. A key focus of the convention was accelerating access to new WHO-recommended regimens for drug-resistant TB (DR-TB).

As part of India’s accelerated rollout of the WHO-recommended six-month, all-oral BPaLM/BPaL regimen for drug-resistant tuberculosis (DR-TB), a total of 136 TB physicians from both public and private sectors gathered for high-level experience-sharing workshops in New Delhi and Mumbai.

PeerLINC concluded a three-day online training on new regimens for drug-resistant tuberculosis and other special TB topics. Participants included National TB Program (NTP) managers across Mongolia. Knowledge areas covered included updates to WHO-recommended regimens, including BPaL/M, managing adverse drug reactions, DR-TB in pregnancy, TB-diabetes comorbidity, and modified regimens for drug-susceptible TB in special cases.

PeerLINC recently welcomed a delegation from Bangladesh’s National Tuberculosis Program (NTP) to a weeklong capacity-building program aimed at accelerating the country’s transition to shorter, safer treatment regimens for drug-resistant tuberculosis (DR-TB). The training combined interactive lectures, workshops, and field visits across Metro Manila to offer a comprehensive view of implementing the WHO-recommended six-month BPaLM/BPaL regimens.